SciSparc has been granted by Nasdaq that it has been granted an additional 180-day compliance period, or until March 4, 2024 to regain compliance with Nasdaq’s minimum bid price rule. Nasdaq’s determination is based on the company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on Nasdaq, with the exception of the bid price requirement, and the company’s written notice of its intention to cure the deficiency during the second compliance period and if necessary, by effecting a reverse stock split. If at any time before March 4, 2024, the closing bid price of the company’s ordinary shares is at least $1.00 per share for a minimum of 10 consecutive business days, the company will regain compliance with this Nasdaq rule and this matter will be closed. This current notification from Nasdaq has no immediate effect on the listing or trading of the Company’s ordinary shares, which will continue to trade on Nasdaq under the symbol “SPRC.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SPRC:
- SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
- SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
- SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering
- SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
- SciSparc prices 6.5M shares at 20c in underwritten public offering